Revenue Surge Masks Profit Collapse — Projects Ahead of Problems

The Q1 headline is a paradox: revenue hit ₹304.2 Cr on a 76% YoY surge, and EBITDA more than doubled to ₹25 Cr. Yet net profit collapsed to ₹3.2 Cr, a 78% decline. Management's gross margin recovered 3 percentage points to 33%, signaling better product mix and cost discipline. But when you bridge EBITDA down to PAT, a ₹21.8 Cr post-EBITDA haircut emerges — depreciation, interest, and tax drag from the ₹750 Cr 7-ACA backward integration capex project and merger integration costs. The quarter reveals the truth: near-term profitability is being crushed by long-term investment. This is not a quality miss; it is a capex timing issue.

FY27 guidance withdrawn. Prior guidance (four FY-2026 calls) projected 10–15% FY27 growth. Q1 delivered +76% on merger-restated basis (+15.6% organic, +28% QoQ), but management declined to raise or confirm FY27 guidance, saying 'not prudent' at this time. Signal: caution on sustaining margin recovery and uncertainty on near-term demand.

Gross margin recovery, but profit-neutral. Gross margin expanded 3 ppts (30% → 33%), driven by product mix and cost discipline. EBITDA more than doubled to ₹25 Cr. But SG&A, depreciation, and interest absorption left PAT flat-to-negative, erasing the operational gain. Management did not address this on the call; investors had to infer it.

Projects remain on track; capex drag now transparent. 7-ACA capex ₹750 Cr and cefiderocol capex USD 20–25 million are completing in FY27 (March 2027 commercial batch, December 2026 facility). The magnitude of depreciation burden is now visible in the PAT collapse, signaling that near-term profitability recovery is postponed to FY28 when revenue contribution begins.

The result announcement (Friday, August 14, 2026) triggered an immediate sell-off: day 1 down 4.41%, day 3 down 6.33%, day 5 down 3.6%. The market's verdict was swift — headline growth does not offset profit collapse. The stock currently trades at ₹1038.1, down 8.4% from its all-time high of ₹1133, but still 116% above its 52-week low. Technically, it sits above its 20-, 50-, and 200-day simple moving averages, suggesting underlying support, though RSI 55 (neutral) shows no momentum rally is forming.

Ownership shift matters. Foreign institutional investors (FII) have trimmed to 0.81% (from 0.87% prior, a -0.06 pp decline). Domestic institutional investors (DII) are steady at 20.75% (from 20.25%, +0.5 pp). Promoters hold 69.84% unchanged. The FII retreat post-result is consistent with the 4–6% price sell-off and suggests stock-specific concern (capex duration, margin recovery timeline) is driving exits.

The price action and ownership flow confirm the fundamental read: investors see a company with a multi-year capex cycle that will suppress profitability until FY28. The 8.4% drawdown from ATH is not deep, but it signals that 'growth story' optimism has faded. The real test will be Q2 and H2 FY27 results — if PAT recovers to 3–4% NPM and management guides H2 positively, the narrative flips. If PAT stays at 1–1.5%, the street will adopt a 'show-me' stance, waiting for 7-ACA revenue.

Adjusted net profit (organic PAT, ex. extraordinary items). Reported PAT is noisy from capex depreciation swings. The real metric is sustainable operating profit — gross margin × volumes, minus stable SG&A and interest, before depreciation. If management articulates adjusted PAT recovering to ₹8–10 Cr (2.5–3% NPM) by Q4 FY27 or Q1 FY28, the capex cycle is entering its final stretch and the market will begin pricing in FY28 upside. If adjusted PAT stays at 3–5 Cr (1–1.5% NPM) through H2, the market will wait for project revenue before re-rating — and the stock could drift lower on 'show-me' sentiment.